| Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency AM Cepika, Y Sato, JMH Liu, MJ Uyeda, R Bacchetta, MG Roncarolo Journal of Allergy and Clinical Immunology 142 (6), 1679-1695, 2018 | 138 | 2018 |
| Metabolomic profiling of pompe disease-induced pluripotent stem cell-derived cardiomyocytes reveals that oxidative stress is associated with cardiac and skeletal muscle pathology Y Sato, H Kobayashi, T Higuchi, Y Shimada, H Ida, T Ohashi Stem Cells Translational Medicine 6 (1), 31-39, 2017 | 47 | 2017 |
| Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient Y Sato, H Kobayashi, T Higuchi, Y Shimada, T Era, S Kimura, Y Eto, H Ida, ... Molecular Therapy Methods & Clinical Development 2, 2015 | 46 | 2015 |
| The production of human glucocerebrosidase in glyco‐engineered Nicotiana benthamiana plants J Limkul, S Iizuka, Y Sato, R Misaki, T Ohashi, T Ohashi, K Fujiyama Plant Biotechnology Journal 14 (8), 1682-1694, 2016 | 43 | 2016 |
| TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle Y Sato, H Kobayashi, T Higuchi, Y Shimada, H Ida, T Ohashi Molecular Therapy Methods & Clinical Development 3, 2016 | 38 | 2016 |
| Human‐engineered Treg‐like cells suppress FOXP3‐deficient T cells but preserve adaptive immune responses in vivo Y Sato, L Passerini, BD Piening, MJ Uyeda, M Goodwin, S Gregori, ... Clinical & Translational Immunology 9 (11), e1214, 2020 | 37 | 2020 |
| Co-expression of FOXP3FL and FOXP3Δ2 isoforms is required for optimal treg-like cell phenotypes and suppressive function Y Sato, J Liu, E Lee, R Perriman, MG Roncarolo, R Bacchetta Frontiers in immunology 12, 752394, 2021 | 20 | 2021 |
| Towards gene therapy for IPEX syndrome S Borna, E Lee, Y Sato, R Bacchetta European Journal of Immunology 52 (5), 705-716, 2022 | 19 | 2022 |
| Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy Y Sato, M Fujiwara, H Kobayashi, H Ida Pediatric Cardiology 34, 2077-2079, 2013 | 18 | 2013 |
| Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice Y Sato, H Ida, T Ohashi Clinical Immunology 178, 56-63, 2017 | 9 | 2017 |
| P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler–Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 … H Kobayashi, M Ariga, Y Sato, M Fujiwara, N Fukasawa, T Fukuda, ... JIMD Reports, Volume 41: Focus Issue: Adults and Metabolism, 101-107, 2018 | 7 | 2018 |
| Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy … Y Sato, M Fujiwara, H Kobayashi, M Yoshitake, K Hashimoto, Y Oto, H Ida Molecular Genetics and Metabolism Reports 5, 94-97, 2015 | 7 | 2015 |
| Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy JMH Liu, P Chen, MJ Uyeda, B Cieniewicz, EC Sayitoglu, BC Thomas, ... Cytotherapy 23 (11), 1017-1028, 2021 | 6 | 2021 |
| Systemic accumulation of undigested lysosomal metabolites in an autopsy case of mucolipidosis type II; autophagic dysfunction in cardiomyocyte Y Sato, H Kobayashi, S Sato, Y Shimada, T Fukuda, Y Eto, T Ohashi, ... Molecular Genetics and Metabolism 112 (3), 224-228, 2014 | 5 | 2014 |
| A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products Y Sato, A Nathan, S Shipp, JF Wright, KM Tate, P Wani, MG Roncarolo, ... Molecular Therapy-Methods & Clinical Development 31, 2023 | 3 | 2023 |
| Immunoregulatory cell therapy with lentiviral-mediated FOXP3 converted CD4+ T cells into Treg cells: towards the proof-of-concept application in IPEX syndrome Y Sato, L Passerini, M Roncarolo, R Bacchetta Cytotherapy 21 (5), S14, 2019 | 3 | 2019 |
| Non-canonical NFKB signaling endows suppressive function through FOXP3-dependent regulatory T cell program Y Sato, E Osada, Y Manome Heliyon 9 (12), 2023 | 2 | 2023 |
| Lentiviral gene transfer to iPS cells: toward the cardiomyocyte differentiation of pompe disease-specific iPS cells Y Sato, T Higuchi, H Kobayashi, S Minamisawa, H Ida, T Ohashi Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function …, 2016 | 1 | 2016 |
| A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products Y Sato, A Nathan, S Shipp, JF Wright, KM Tate, P Wani, MG Roncarolo, ... Molecular Therapy Methods & Clinical Development 32 (1), 2024 | | 2024 |
| Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy R Bacchetta, MG Roncarolo, Y Sato, L Naldini, L Passerini US Patent App. 17/615,766, 2022 | | 2022 |
